Audentes Therapeutics (BOLD)

37.65 -2.03 (5.12%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/13/18 *Est.)

Latest Headlines

Form 4 Audentes Therapeutics, For: Sep 18 Filed by: Patterson Matthew R September 20, 2018 7:02 PM - SEC Filing Form SC 13G/A Audentes Therapeutics, Filed by: FMR LLC September 10, 2018 10:04 AM - SEC Filing B.Riley/FBR Starts Audentes Therapeutics (BOLD) at Sell September 7, 2018 4:03 AM - StreetInsider Audentes Therapeutics to Participate in Upcoming Investor Conferences August 29, 2018 8:00 AM - PR NewsWire RMAT Designation Signals Audentes Therapeutics (BOLD) Could File For Reg Approval Based On Ph 1/2 Data - Mizuho August 22, 2018 6:34 AM - StreetInsider Audentes (BOLD) Announces RMAT Designation Granted by FDA to AT132 for Treatment of X-Linked Myotubular Myopathy August 21, 2018 8:01 AM - StreetInsider Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy August 21, 2018 8:00 AM - PR NewsWire UPDATE: Citi Starts Audentes Therapeutics (BOLD) at Neutral August 21, 2018 5:09 AM - StreetInsider Form 10-Q/A Audentes Therapeutics, For: Mar 31 August 10, 2018 4:32 PM - SEC Filing Form 10-K/A Audentes Therapeutics, For: Dec 31 August 10, 2018 4:22 PM - SEC Filing Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference August 9, 2018 8:00 AM - PR NewsWire Mizuho Securities Upgrades Audentes Therapeutics (BOLD) to Buy August 8, 2018 5:03 AM - StreetInsider Audentes Therapeutics (BOLD) PT Raised to $32 at Evercore ISI August 7, 2018 3:01 PM - StreetInsider Audentes Therapeutics (BOLD) Announces Update on ASPIRO Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy August 7, 2018 6:23 AM - StreetInsider Audentes Therapeutics (BOLD) Misses Q2 EPS by 7c August 7, 2018 6:20 AM - StreetInsider Form 10-Q Audentes Therapeutics, For: Jun 30 August 7, 2018 6:12 AM - SEC Filing Form 8-K Audentes Therapeutics, For: Aug 07 August 7, 2018 6:11 AM - SEC Filing Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy August 7, 2018 6:00 AM - PR NewsWire Audentes to Release Second Quarter 2018 Financial Results and Provide Update on ASPIRO, the Phase 1/2 study of AT132 in Patients with X-Linked Myotubular Myopathy July 31, 2018 8:00 AM - PR NewsWire Form 4 Audentes Therapeutics, For: Jul 02 Filed by: PRASAD SUYASH July 5, 2018 6:36 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jul 02 Filed by: Patterson Matthew R July 5, 2018 6:35 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 25 Filed by: NEWMAN MARY June 27, 2018 6:53 PM - SEC Filing Form 4 Audentes Therapeutics, For: Jun 25 Filed by: LANGE LOUIS G June 27, 2018 6:52 PM - SEC Filing Chardan Capital Markets Starts Audentes Therapeutics (BOLD) at Neutral June 26, 2018 4:54 AM - StreetInsider NodThera secures £28 million ($40 million) Series A Financing June 25, 2018 2:00 AM - StreetInsider Full Article List